BIOC
(NASDAQ)
0.2789
-0.0228  (-8.17%)
Volume (24h): 7.29M Day Range: 0.2695 - 0.2990
Market Cap: 25.85M 52W Range: 0.2112 - 2.10
Mar-28-20 12:23PM US$1.00: That's What Analysts Think Biocept, Inc. (NASDAQ:BIOC) Is Worth After Its Latest ResultsSimply Wall St.
Mar-26-20 12:05PM Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician AssociationPR Newswire
Mar-25-20 08:05PM Biocept Reports 2019 Fourth Quarter and Full Year Financial ResultsPR Newswire
06:30PM Biocept, Inc. to Host Earnings CallACCESSWIRE
Mar-18-20 12:30PM Biocept, Inc. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN NetworkACCESSWIRE
12:05PM Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020PR Newswire
Mar-11-20 01:23PM Biotech Maven Hal Mintz Snaps Up These 3 Small Biotech StocksTipRanks
Mar-09-20 12:05PM Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated MutationsPR Newswire
Mar-05-20 01:30PM Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-MarketPR Newswire
Mar-02-20 03:48PM Biocept's stock plummets on heavy volume after share offering prices at deep discountMarketWatch
01:30PM Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-MarketPR Newswire
Feb-14-20 01:05PM Biocept Appoints Cory J. Dunn Senior Vice President of Commercial OperationsPR Newswire
Feb-10-20 01:05PM Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician AssociationPR Newswire
Feb-04-20 01:05PM Biocept to Present at the 22nd Annual BIO CEO & Investor ConferencePR Newswire
Jan-14-20 01:05PM Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal FluidPR Newswire
Jan-12-20 01:22PM How Does Investing In Biocept, Inc. (NASDAQ:BIOC) Impact The Volatility Of Your Portfolio?Simply Wall St.
Jan-08-20 02:00PM Biocept, Inc. Awarded United States Patent for the Use of Antibodies in Combination with Any Solid Surface to Detect Any Target Cell of Interest - from Any Sample TypePR Newswire
Dec-12-19 01:00PM Biocept Announces Closing of $10.0 Million Underwritten Public OfferingPR Newswire
Dec-10-19 12:56PM The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect SharesBenzinga
Dec-09-19 02:15PM Biocept Announces Pricing of $10.0 Million Underwritten Public OfferingPR Newswire
Dec-03-19 01:05PM Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®PR Newswire
Nov-21-19 01:05PM Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with CancerPR Newswire
Nov-13-19 09:05PM Biocept Reports Third Quarter 2019 Financial ResultsPR Newswire
Nov-07-19 01:05PM Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in EuropePR Newswire
Nov-06-19 01:05PM Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019PR Newswire
Nov-04-19 01:05PM Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual MeetingPR Newswire
Oct-14-19 02:05PM Why Biocept, Inc.'s (NASDAQ:BIOC) CEO Pay Matters To YouSimply Wall St.
Oct-07-19 12:05PM Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONEPR Newswire
Oct-03-19 12:05PM Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection PlatformPR Newswire
Sep-03-19 12:05PM Biocept to Present at Two Investment Conferences in SeptemberPR Newswire
Aug-22-19 12:05PM High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung CancerPR Newswire
Aug-13-19 12:05PM Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer CellsPR Newswire
Aug-12-19 08:05PM Biocept Reports Second Quarter 2019 Financial ResultsPR Newswire
06:30PM Biocept, Inc. to Host Earnings CallACCESSWIRE
Aug-05-19 12:05PM Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019PR Newswire
Jul-22-19 12:05PM Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®PR Newswire
Jul-16-19 05:31PM Does Biocept, Inc. (NASDAQ:BIOC) Have A High Beta?Simply Wall St.
Jun-18-19 12:05PM Biocept Announces Commercial Launch of Target Selector™ NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific PanelPR Newswire
Jun-03-19 12:05PM Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4PR Newswire
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)